Clinical Trial Update: Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients [Phase 2]

View source ↗

Summary

A single-arm Phase 2 trial of afatinib (BIBW 2992) in demographically and genotypically selected non-small cell lung cancer patients has completed, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2013-10-23